*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. When the Competition Authority practices "name and shame",... the Paris Court of Appeal declares itself incompetent to hear the case. How far can the Competition Authority go in communicating its decisions? This is the underlying question raised by the present case. Following the adoption on 9 September 2020 of its decision No 20-D-11 in which it fined the Novartis group and the Roche/Genentech group €444 million (€385 million to Novartis and €59.7 million to the Roche group) for having abused their collective dominant position on the French market for the treatment of age-related macular degeneration (AMD) By implementing two distinct but similar
ALERTS: PROCEDURES - FRANCE - JURISDICTION - COMMUNICATION - ABUSE OF DOMINANT POSITION - HEALTH CARE
Jurisdiction: The Paris Court of Appeal declares that it has no jurisdiction to hear challenges to the communication policy of the French Competition Authority (Roche)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.